Bill Henshaw, Axcella Health CEO
December 15, 2022 08:24 AM EST
Coronavirus

Ax­cel­la re­duces work­force by 85%, pri­or­i­tizes long Covid drug re­search

Katherine Lewin

News Reporter

Af­ter miss­ing its pri­ma­ry goal in Phase IIa tri­als for its long Covid drug, Ax­cel­la Health an­nounced Wednes­day that it’s cut­ting 85% of its work­force …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times